SUTENT 50 mg, hard capsule 28 capsules
Active ingredients: Sunitinib malate, Sunitinib
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule28 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SUTENT 50 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 28 plaquette(s) thermoformée(s) polychlortrifluoroéthylène PVC de 1 gélule(s)
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 Nov 2008
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63841059CIP73821045CIP133400938210453Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SUNITINIBgélule | 50 mg · une gélule | FT |
| MALATE DE SUNITINIBgélule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.